
Chlorthalidone (12.5mg) + Telmisartan (40mg)
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Medical applications
Eritel CH 40 Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Chlorthalidone 12.5 mg. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, which results in vasodilation and reduced blood pressure. Chlorthalidone is a thiazide-like diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, leading to decreased plasma volume and peripheral vascular resistance. The synergistic action of these two agents provides effective management of hypertension, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Eritel CH 40 Tablet is indicated for the treatment of essential hypertension in patients who require combination therapy to achieve adequate blood pressure control. It is contraindicated in patients with hypersensitivity to any component, anuria, or severe renal impairment. Caution is advised in patients with electrolyte imbalances, hepatic dysfunction, or gout. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Eritel CH 40 Tablet should be used under medical supervision with adherence to prescribed dosage and lifestyle modifications for optimal therapeutic outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Eritel CH 40 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Eritel CH 40 Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Medical Advice
Eritel CH 40 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Eritel CH 40 Tablet may be needed. Please consult your doctor. Use of Eritel CH 40 Tablet is not recommended in these patients.
Exercise Caution
Eritel CH 40 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Eritel CH 40 Tablet should be used with caution in patients with liver disease. Dose adjustment of Eritel CH 40 Tablet may be needed. Please consult your doctor. Use of Eritel CH 40 Tablet is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Eritel CH 40 Tablet

Telmisartan (40mg) + Chlorthalidone (12.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Medical applications
Eritel CH 40 Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Chlorthalidone 12.5 mg. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, which results in vasodilation and reduced blood pressure. Chlorthalidone is a thiazide-like diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, leading to decreased plasma volume and peripheral vascular resistance. The synergistic action of these two agents provides effective management of hypertension, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Eritel CH 40 Tablet is indicated for the treatment of essential hypertension in patients who require combination therapy to achieve adequate blood pressure control. It is contraindicated in patients with hypersensitivity to any component, anuria, or severe renal impairment. Caution is advised in patients with electrolyte imbalances, hepatic dysfunction, or gout. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Eritel CH 40 Tablet should be used under medical supervision with adherence to prescribed dosage and lifestyle modifications for optimal therapeutic outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Eritel CH 40 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Eritel CH 40 Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Medical Advice
Eritel CH 40 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Eritel CH 40 Tablet may be needed. Please consult your doctor. Use of Eritel CH 40 Tablet is not recommended in these patients.
Exercise Caution
Eritel CH 40 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Eritel CH 40 Tablet should be used with caution in patients with liver disease. Dose adjustment of Eritel CH 40 Tablet may be needed. Please consult your doctor. Use of Eritel CH 40 Tablet is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Eritel CH 40 Tablet















